Jasper Therapeutics, Inc. (NASDAQ:JSPR) Given Average Recommendation of “Hold” by Brokerages

Shares of Jasper Therapeutics, Inc. (NASDAQ:JSPR) have been given an average rating of “Hold” by the twelve research firms that are covering the stock, Marketbeat.com reports. One analyst has rated the stock with a sell recommendation, six have given a hold recommendation and five have assigned a buy recommendation to the company. The average 1 year target price among brokers that have issued ratings on the stock in the last year is $13.1429.

A number of equities analysts have weighed in on the company. Weiss Ratings reiterated a “sell (e+)” rating on shares of Jasper Therapeutics in a research note on Tuesday, April 21st. Royal Bank Of Canada set a $3.00 price objective on Jasper Therapeutics and gave the company a “sector perform” rating in a report on Friday, May 15th. UBS Group assumed coverage on Jasper Therapeutics in a research note on Monday, March 23rd. They issued a “neutral” rating on the stock. Finally, TD Cowen lowered Jasper Therapeutics from a “buy” rating to a “hold” rating in a report on Friday, May 15th.

Institutional Investors Weigh In On Jasper Therapeutics

A number of hedge funds and other institutional investors have recently made changes to their positions in the company. Knott David M Jr increased its holdings in shares of Jasper Therapeutics by 5.8% during the 4th quarter. Knott David M Jr now owns 181,389 shares of the company’s stock valued at $332,000 after purchasing an additional 10,000 shares in the last quarter. Acadian Asset Management LLC purchased a new stake in Jasper Therapeutics during the first quarter worth $46,000. Engineers Gate Manager LP purchased a new stake in Jasper Therapeutics during the second quarter worth $78,000. Renaissance Technologies LLC grew its position in Jasper Therapeutics by 9.0% during the fourth quarter. Renaissance Technologies LLC now owns 227,183 shares of the company’s stock valued at $416,000 after buying an additional 18,683 shares during the period. Finally, Panagora Asset Management Inc. acquired a new stake in Jasper Therapeutics during the fourth quarter valued at $35,000. Institutional investors and hedge funds own 79.85% of the company’s stock.

Jasper Therapeutics Price Performance

JSPR stock opened at $0.43 on Friday. The firm’s fifty day simple moving average is $0.68 and its 200-day simple moving average is $1.12. The company has a market capitalization of $11.99 million, a P/E ratio of -0.13 and a beta of 3.07. Jasper Therapeutics has a 12 month low of $0.32 and a 12 month high of $7.19.

Jasper Therapeutics (NASDAQ:JSPR) last issued its earnings results on Thursday, May 14th. The company reported ($0.38) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.46) by $0.08. As a group, sell-side analysts forecast that Jasper Therapeutics will post -1.67 earnings per share for the current year.

Jasper Therapeutics Company Profile

Jasper Therapeutics, Inc (NASDAQ: JSPR) is a clinical-stage biopharmaceutical company focused on translating advances in immunobiology into therapies for serious and rare diseases with unmet medical needs. The company’s research and development efforts center on engineered biologics and cell-based approaches designed to address complications in hematologic conditions and improve outcomes in transplant medicine.

Central to Jasper’s pipeline is JSP191, a monoclonal antibody targeting the CD117 receptor, which is being evaluated to enhance donor hematopoietic stem cell engraftment in patients undergoing stem cell transplantation.